Synthetic-Biology-Startups-Biotechnology-SharedImg-StartUs-Insights-noresize

5 Top Synthetic Biology Startups Impacting The BioTech Sector

We analyzed 486 synthetic biology startups impacting the biotech sector.​ Cysbio, Siolta Therapeutics, Kinnva, Genecis & Asimov develop 5 top solutions to watch out for. Learn more in our Global Startup Heat Map!

Our Innovation Analysts recently looked into emerging technologies and up-and-coming startups working on solutions for the biotech sector. As there is a large number of startups working on a wide variety of solutions, we want to share our insights with you. This time, we are taking a look at 5 promising synthetic biology startups.

Heat Map: 5 Top Synthetic Biology Startups

Using our StartUs Insights Platform, covering 1.116.000+ startups & emerging companies, we looked at innovation in the field of biotechnology. For this research, we identified 486 relevant solutions and picked 5 to showcase below. These companies were chosen based on a data-driven startup scouting approach, taking into account factors such as location, founding year, and technology among others. Depending on your specific criteria, the top picks might look entirely different.

The Global Startup Heat Map below highlights 5 startups & emerging companies developing innovative synthetic biology solutions. Moreover, the Heat Map reveals regions that observe a high startup activity and illustrates the geographic distribution of all 486 companies we analyzed for this specific topic.

Synthetic-Biology-Startups-Biotechnology-Heat-Map-StartUs-Insights-noresize

Click to download

Which startups develop the other 481 solutions?

 

Cysbio – Bacterial Cell Factories

The biotech industry has long used genetically modified bacteria to produce highly valuable biochemicals for pharma, materials, and food, among other industries. However, it remains an uphill task to make microbes produce chemicals that they cannot naturally synthesize. With advances in synthetic biology and metabolic engineering, it is now easier to manipulate bacteria and yeast to produce various products. The application of engineering design principles enables the optimization of the production process for higher yields.

Cysbio is a Danish startup that uses synthetic biology to construct bacterial cell factories. The startup’s proprietary processes produce biochemicals such as amino acids for pharma, food, and feed markets. With metabolic and enzyme engineering, The startup imparts novel functionalities to biochemicals with its patented sulfation technology that produces sulfated biochemicals. This solution finds applications in antifouling agents, nutraceutical ingredients, and precursors for functional polymers.

Siolta Therapeutics – Therapeutic Microbial Consortia

Over the last decade, there has been extensive research on how the human microbiome influences health. Solutions, that develop and maintain a healthy microbiome to prevent and treat a wide range of disorders, are on the rise. With modernizing lifestyles, the risk of chronic allergies is greater than ever before. However, therapeutic microbial interventions in the form of probiotics hold promise for the prevention of allergic diseases.

The US-based startup Siolta Therapeutics develops therapeutic microbial consortia to prevent and treat inflammatory diseases. It analyzes clinical data and rationally designs mixed-species therapeutics for oral supplementation. Unlike current care treatments for allergies, the microbiome-based approach acts before the initiation of immune dysfunction cascade. The startup’s lead candidate, STMC-103H, is under investigation for the treatment of allergic asthma, as well as other chronic inflammatory diseases such as atopic dermatitis and allergic rhinitis.

Kinnva – Aquaculture Feed

Aquaculture is a primary source of animal protein for millions of people and supports the economies of many communities. Growth in the industry is largely limited by a lack of access to affordable and reliable feed sources. This is because growing feed crops takes away land from other important crops. Synthetic biology-based solutions replace plants with fermentation to produce feed and other plant-based products in a sustainable and scalable manner.

Kinnva is a Singapore-based startup that uses fermentation and intensified processing methods to produce high-value biochemicals and biomaterials. The startup’s proprietary Integrated Methane Platform converts waste gases such as methane to value-added products. KinnFeed, the startup’s aquaculture feed, provides high-quality protein resulting from a stable production process. The solution is eco-friendly and uses far less water and land to produce constant amounts of feed.

Genecis – Bioplastics

Petroleum-based plastics produce high levels of pollution. To add, plastics do not degrade easily, such as microplastics in the oceans, and last for hundreds to thousands of years. Another common waste product in abundance is food waste. Though compostable, it produces methane, a greenhouse gas (GHG), when dumped in landfills. Bioplastics simultaneously address both of these problems by turning food waste into compostable plastic alternatives.

Candian startup Genecis uses synthetic biology to convert waste into high-value materials. The startup diverts food waste from landfills and uses bacteria to turn it into compostable polyhydroxyalkanoate (PHA) bioplastics. This solution serves food, agriculture, textiles, and other industries looking to replace plastics with sustainable alternatives. Unlike traditional plastics, PHA plastics degrade within a year.

Asimov – Mammalian Synthetic Biology

Unlike bacterial and yeast-based synthetic biology, mammalian synthetic biology is in its nascent stage. This holds promise for solutions that would be very difficult or near impossible in microbial systems. For instance, cells engineered as biosensors that also produce or trigger the production of therapeutic proteins. The success of mammalian synthetic biology depends on the design quality of synthetic circuits and requires interdisciplinary efforts.

Asimov is a US-based startup that offers a genetic design platform for mammalian synthetic biology. The startup integrates synthetic biology, computational modeling, multi-omics measurement, and machine learning in a single platform to advance therapeutic applications. Asimov’s computer-aided design tools enable easier engineering of living systems. The startup focuses on protein biologics, viral vectors, and cell & gene therapy.

What About The Other 481 Solutions?

While we believe data is key to creating insights it can be easy to be overwhelmed by it. Our ambition is to create a comprehensive overview and provide actionable innovation intelligence so you can achieve your goals faster. The 5 synthetic biology startups showcased above are promising examples out of 486 we analyzed for this article. To identify the most relevant solutions based on your specific criteria, get in touch.

Get your Pharma Innovation Report!
We’ll deliver it straight to your inbox!






    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    Looking for a custom analysis?
    Looking for a custom analysis?




      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Related Articles

      Resources
      Get your BioTech Innovation Report!
      We’ll deliver it straight to your inbox!






        This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
        Get your Pharma Innovation Report!
        We’ll deliver it straight to your inbox!






          This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
          Get a sneak peak into the future of Artificial Intelligence!
          We'll contact you!






            This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
            Get a sneak peak into the future of Advanced Analytics!
            We'll contact you!






              This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
              Subscribe to our Newsletter!



                This field is required.

                This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.